Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002361 · ClinicalTrials.gov registry record · Phase 2
Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors
A Phase 2 study of HIV Infections, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 8
- Study locations
NCT00002361: Completed Phase 2 study of HIV Infections, sponsored by Merck Sharp & Dohme.
NCT00002361 is a Phase 2 study of HIV Infections that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 30 participants, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower). The trial reports 8 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002361, a Phase 2 study of HIV Infections, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination containing indinavir and ritonavir to HIV-positive patients who have failed previous treatment with protease inhibitors.
Conditions Studied
Interventions
- DRUG Ritonavir
- DRUG Indinavir sulfate
Study Locations (8)
California
- LAC / USC Med Ctr / Infectious Diseases - Los Angeles
Florida
- Univ of Miami School of Medicine - Miami
Illinois
- Northwestern Univ / Div of Infect Diseases - Chicago
Maryland
- Chase Braxton Health Service - Baltimore
Massachusetts
- Beth Israel Deaconess Med Ctr - Boston
New York
- Albany Med College - Albany
North Carolina
- Univ of North Carolina / Infectious Disease Division - Chapel Hill
Oregon
- The Research and Education Group - Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Phase | Phase 2 |
What the finished NCT00002361 record still lists
NCT00002361 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 446-participant average among 542 other HIV Infections trials with a reported enrollment target (93% lower).
The record links to 1 condition, with HIV Infections appearing as the primary indexed condition, and to 2 interventions - of which Ritonavir is the first listed.
NCT00002361 lists 8 locations in 8 states (California, Florida, Illinois).
Frequently Asked Questions
What is clinical trial NCT00002361 about?
NCT00002361 is a clinical study titled "Safety and Effectiveness of an Anti-HIV Drug Combination in HIV-Positive Patients Who Have Failed Previous Treatment With Protease Inhibitors". The purpose of this study is to see if it is safe and effective to give an anti-HIV drug combination containing indinavir and ritonavir to HIV-positive patients who have failed previous treatment with protease inhibitors.
What is the current status of trial NCT00002361?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 30 participants.
What conditions does trial NCT00002361 study?
This clinical trial studies the following conditions: HIV Infections.
What interventions are being tested in trial NCT00002361?
The interventions under investigation include: Ritonavir (DRUG), Indinavir sulfate (DRUG).
Who is sponsoring clinical trial NCT00002361?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00002361 being conducted?
This trial has 8 study locations across California, Florida, Illinois, Maryland, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV Infections
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00002361's enrollment target sits among peer trials
30 426th of 542 higher than 102 of 542 other HIV Infections trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HIV Infections trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
RECRUITING · Phase 2
-
Microbiome Metabolites and Alcohol in HIV to Reduce CVD RCT
RECRUITING · Phase 2
-
Cholesterol and Inflammation Lowering Via Bempedoic Acid, an ACL-inhibiting Regimen in HIV Trial (CLEAR HIV Trial)
RECRUITING · Phase 2
-
Imaging Immune Activation in HIV by PET-MR
RECRUITING · Phase 2
-
A Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a New Formulation of Cabotegravir Long-Acting Administered Intramuscularly in a 4-month Dosing Interval (Q4M)
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer